Evidence map›Paper›PMID 29558509›Full record

ArticlePloS one2018

Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism.

Luis Jara-Palomares, Remedios Otero, David Jimenez, Juan Manuel Praena-Fernandez, Carme Font, Conxita Falga, Silvia Soler, David Riesco, Peter Verhamme, Manuel Monreal and 1 more

Open access · goldAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 2 countries.

Luis Jara-PalomaresDepartment of Pneumonology, Medical Surgical Unit of Respiratory Diseases, Instituto de Biomedicina de Sevilla (IBiS), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Hospital Universitario Virgen del Rocío, Seville, Spain.ORCID 0000-0002-4125-3376
Remedios OteroDepartment of Pneumonology, Medical Surgical Unit of Respiratory Diseases, Instituto de Biomedicina de Sevilla (IBiS), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Hospital Universitario Virgen del Rocío, Seville, Spain.
David JimenezRespiratory Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
Juan Manuel Praena-FernandezStatistics, Methodology and Research Evaluation Unit, Hospital Universitario Virgen del Rocío, Seville, Spain.
Carme FontDepartment of Medical Oncology, Hospital Clínic, Barcelona, Spain.
Conxita FalgaDepartment of Internal Medicine, Consorci Hospitalari de Mataró, Barcelona, Spain.
Silvia SolerDepartment of Internal Medicine, Hospital Olot i Comarcal de la Garrotxa, Gerona, Spain.
David RiescoDepartment of Internal Medicine, Hospital Sant Pau i Santa Tecla, Tarragona, Spain.
Peter VerhammeVascular Medicine and Haemostasis, University of Leuven, Leuven, Belgium.
Manuel MonrealDepartment of Internal Medicine, Hospital Universitario Germans Trias i Pujol de Badalona, Barcelona, Universidad Católica de Murcia, Spain.
RIETE Registry
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESHospital Clínic de Barcelona · ESHospital Comarcal de Inca · ESHospital de Mataró · ESHospital Sant Pau i Santa Tecla · ESHospital Universitario Virgen del Rocío · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESKU Leuven · BEUniversidad Católica de Murcia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The usefulness of a diagnostic workup for occult cancer in patients with venous thromboembolism (VTE) is controversial. We used the RIETE (Registro Informatizado Enfermedad Trombo Embólica) database to perform a nested case-control study to validate a prognostic score that identifies patients with unprovoked VTE at increased risk for cancer. We dichotomized patients as having low- (≤2 points) or high (≥3 points) risk for cancer, and tried to validate the score at 12 and 24 months. From January 2014 to October 2016, 11,695 VTE patients were recruited. Of these, 1,360 with unprovoked VTE (11.6%) were eligible for the study. At 12 months, 52 patients (3.8%; 95%CI: 2.9-5%) were diagnosed with cancer. Among 905 patients (67%) scoring ≤2 points, 22 (2.4%) had cancer. Among 455 scoring ≥3 points, 30 (6.6%) had cancer (hazard ratio 2.8; 95%CI 1.6-5; p<0.01). C-statistic was 0.63 (95%CI 0.55-0.71). At 24 months, 58 patients (4.3%; 95%CI: 3.3-5.5%) were diagnosed with cancer. Among 905 patients scoring ≤2 points, 26 (2.9%) had cancer. Among 455 patients scoring ≥3 points, 32 (7%) had cancer (hazard ratio 2.6; 95%CI 1.5-4.3; p<0.01). C-statistic was 0.61 (95%CI, 0.54-0.69). We validated our prognostic score at 12 and 24 months, although prospective cohort validation is needed. This may help to identify patients for whom more extensive screening workup may be required.

Indexed as

AdultAgedAged, 80 and overCase-Control StudiesDatabases, FactualDiagnosis, DifferentialEarly Detection of CancerFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasmsNeoplasms, Unknown PrimaryPrognosisRegistries

Identifiers

PMID29558509
PMCPMC5860754
OpenAlexW2789649572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.